Candriam S.C.A. Mirum Pharmaceuticals, Inc. Transaction History
Candriam S.C.A.
- $16.9 Billion
- Q4 2024
A detailed history of Candriam S.C.A. transactions in Mirum Pharmaceuticals, Inc. stock. As of the latest transaction made, Candriam S.C.A. holds 429,731 shares of MIRM stock, worth $20.2 Million. This represents 0.1% of its overall portfolio holdings.
Number of Shares
429,731
Previous 508,475
15.49%
Holding current value
$20.2 Million
Previous $19.8 Million
10.39%
% of portfolio
0.1%
Previous 0.12%
Shares
2 transactions
Others Institutions Holding MIRM
# of Institutions
210Shares Held
53.7MCall Options Held
2.6KPut Options Held
99.7K-
Frazier Life Sciences Management, L.P. Menlo Park, CA6.57MShares$309 Million16.29% of portfolio
-
Janus Henderson Group PLC London, X04.58MShares$216 Million0.1% of portfolio
-
Black Rock Inc. New York, NY3.24MShares$152 Million0.0% of portfolio
-
Bvf Inc San Francisco, CA2.8MShares$132 Million4.33% of portfolio
-
Eventide Asset Management, LLC Boston, MA2.61MShares$123 Million2.07% of portfolio
About Mirum Pharmaceuticals, Inc.
- Ticker MIRM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,751,700
- Market Cap $1.73B
- Description
- Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the trea...